GlassScriptPhysician profile
Becky J Bole
NPI 1043621576
$5,585.51
in general payments reported to CMS, 2019-2025
29 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $1,250 · 2023: $1,836 · 2024: $1,000 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.17 | 2021-2025 | |
| Alkermes, INC. | $723.67 | 2021-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $717.34 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $420.79 | 2021-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $414.25 | 2021-2024 | Spravato, Invega Sustenna |
| Corium, LLC | $310.86 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272.79 | 2022-2025 | Caplyta |
| Tris Pharma INC | $265.85 | 2023-2024 | Dyanavel Xr |
| Lundbeck LLC | $220.76 | 2021-2023 | Rexulti |
| Corcept Therapeutics | $213.69 | 2022-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $194.14 | 2021-2024 | Uzedy |
| Eisai INC. | $154.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $138.65 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $104.97 | 2021-2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $102.27 | 2022-2023 | Auvelity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $95.96 | 2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $76.03 | 2023 | Quviviq |
| Novo Nordisk INC | $47.89 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $45.20 | 2022-2025 | Zepbound |
| Xeris Pharmaceuticals, INC. | $41.13 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Takeda Pharmaceuticals U.S.A., INC. | $36.22 | 2022-2024 | Trintellix |
| Indivior INC. | $32.69 | 2022-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $30.91 | 2023 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $29.92 | 2023 | |
| Tandem Diabetes Care, INC. | $21.39 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Braeburn INC. | $19.82 | 2024 | Brixadi |
| Dexcom, INC. | $19.73 | 2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $18.06 | 2025 | |
| Abbott Laboratories | $12.92 | 2023 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Becky Bole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.